Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-05-17
1999-11-02
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241301, 4241341, 4241411, 4241431, 4241521, 4241531, 4241731, 424 9463, 424 9464, 435212, 435215, 435216, 5303871, 5303873, 5303881, 53038822, 53038825, 5303887, A61K 39395, A61K 3849, C07K 1628, C12N 964
Patent
active
059765321
ABSTRACT:
Platelet-specific, chimeric immunoglobulin and immunoglobulin fragments are described. The chimeric molecules are made up of a nonhuman antigen binding region and a human constant region. Preferred immunoglobulins are specific for glycoprotein IIb/IIIa receptor in its complexed form; they block ligand binding to the receptor and prevent platelet aggregation. The immunoglobulins are useful in anti-thrombotic therapy when administered alone or in conjunction with thrombolytic agents, as well as in thrombus imaging.
REFERENCES:
patent: 4772585 (1988-09-01), Sarnoff et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5049132 (1991-09-01), Shaffer et al.
patent: 5114842 (1992-05-01), Plow et al.
patent: 5225181 (1993-07-01), Srivastava et al.
patent: 5275812 (1994-01-01), Gold et al.
patent: 5284751 (1994-02-01), Frelinger, III et al.
patent: 5318899 (1994-06-01), Scarborough et al.
patent: 5336618 (1994-08-01), Coller
patent: 5387413 (1995-02-01), Coller
patent: 5440020 (1995-08-01), Coller
patent: 5446132 (1995-08-01), Reed et al.
patent: 5462752 (1995-10-01), Chao et al.
patent: 5470738 (1995-11-01), Frelinger, III et al.
patent: 5492890 (1996-02-01), Ginsberg et al.
patent: 5578704 (1996-11-01), Kim et al.
Marx, J.L., "Antibodies Made to Order," Science, 229:455-456 (1985).
Dillman, R.O., "Human Antimouse and Antiglobulin Responses to Monoclonal Antibodies," Antibod., Immunoconj., Radiopharm., 3(1):1-15 (1990).
Bovsun, M., "Breakthrough Trial Gives First Hope for Restenosis Drugs," Biotechnology Newswatch, pp. 1, 3-4 (Apr. 18, 1994).
Rote, W.E. et al., "Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. I. Adjunctive Therapy with Monoclonal Antibody 7E3 F(ab').sub.2 Fragment," J. Cardiovasc. Pharm., 23:194-202 (1994).
Charo, I.F. et al., "Platelet glycoproteins IIb and IIIa: Evidence for a family of immunologically and structurally related glycoproteins in mammalian cells," Proc. Natl. Acad. Sci. USA, 83:8351-8355 (1986).
Coller, B.S. et al., "Platelet Vitronectin Receptor Expression Differentiates Iraqi-Jewish from Arab Patients with Glanzmann Thrombasthenia in Israel," Blood, 77 (1):75-83 (1991).
Smith, J.W. et al., "Building Synthetic Antibodies as Adhesive Ligands for Integrins," J. Biol. Chem., 269 (52):32788-32795 (1994).
Asch, E. and E. Pocak, "Vitronectin Binds to Activated Human Platelets and Plays a Role in Platelet Aggregation," J. Clin. Invest., 85:1372-1378 (1990).
Felding, B. and D.A. Cheresh, "Vitronectin and its receptors," Current Biol., 5:864-868 (1993).
Brooks, P.C. et al., "Requirement of Vascular Integrin .alpha..sub.v .beta..sub.3 for Angiogenesis," Science, 264:569-572 (1994).
"Scripps Research Scientists Develop New Technique for Treating Malignant Tumors," Genetic Eng. News, 15 (2): 1 (1995).
Brooks, P.C. et al., "Integrin .alpha..sub.v .beta..sub.3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," Cell, 79: 1157-1164 (1994).
Leavesley, D.I. et al., "Integrin .beta.1- and .beta.3-mediated Endothelial Cell Migration is Triggered through Distinct Signalling Mechanisms," J. Cell. Biol., 121 (1):163-170 (1993).
Ikeda, T. et al., "Osteopontin mRNA is Expressed by Smooth Muscle-derived Foam Cells in Human Atherosclerotic Lesions of the Aorta," J. Clin. Invest., 92: 2814-2820 (1993).
Liaw, L. et al., "The Adhesive and Migratory Effects of Osteopontin are Mediated via Distinct Cell Surface Integrins. Role of .alpha..sub.v .beta..sub.3 in Smooth Muscle Cell Migration to Osteopontin In Vitro," J. Clin. Invest., 95: 713-724 (1995).
Nip, J. et al., "Coordinated Expression of the Vitronectin Receptor and the Urokinase-type Plasminogen Activator Receptor in Metastatic Melanoma Cells," J. Clin. Invest., 95: 2096-2103 (1995).
Charo, I.F. et al., "Platelet Glycoprotein IIb-IIIa-like Proteins Mediate Endothelial Cell Attachment to Adhesive Proteins and the Extracellular Matrix," J. Biol. Chem., 262(21): 9935-9938 (1987).
Morrison, S.L. et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984).
McEver, R.P. and M.N. Martin, "A Monoclonal Antibody to a Membrane Glycoprotein Binds Only to Activated Platelets", J. Biol. Chem., 259(15): 9799-9804 (1984).
Sun, L.K. et al., "Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A", Proc. Natl. Acad. Sci. USA, 84: 214-218 (1987).
Coller, B. et al., "A Murine Monoclonal Antibody That completely Blocks the Binding of Fibrinogen to Platelets Produces a Thrombasthenic-like State in Normal Platelets and Binds to Glycoproteins IIb and/or IIIa", J. Clin. Invest., 72: 325-338 (1983).
Hanson, S.R. et al., "Effects of Monoclonal Antibodies against the Platelet Glycoprotein IIb/IIIa Complex on Thrombosis and Hemostasis in the Baboon", J. Clin. Invest., 81: 149-158 (1988).
Pidard, D. et al., "Interaction of AP-2, a Monoclonal Antibody Specific for the Human Platelet Glycoprotein IIb-IIIa Complex, with Intact Platelets", J. Biol. Chem., 258(20): 12,582-12,586 (1983).
Vermylen, J. et al., "Role of Platelet Activation and Fibrin Formation in Thrombogenesis", J. Am. Coll. Cardiol., 8: 2B-9B (1986).
Sahagan, B.G. et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen", J. Immunol., 137(3): 1066-1074 (1986).
Coller, B.S. and L.E. Scudder, "Inhibition of Dog Platelet Function by In Vivo Infusion of F(ab').sub.2 Fragments of a Monoclonal Antibody to the Platelet Glycoprotein IIb/IIIa Receptor", Blood, 66(6): 1456-1459 (1985).
Coller, B.S. et al., "Antithrombotic Effect of a Monoclonal Antibody to the Platelet Glycoprotein IIb/IIIa Receptor in an Experimental Animal Model", Blood, 68(3): 783-786 (1986).
Gold, H.K. et al., "Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation", Circulation, 77(3): 670-677 (1988).
Yasuda, T. et al., "Monoclonal Antibody against the Platelet Glycoprotein (GP) IIb/IIIa Receptor Prevents Coronary Artery Reocclusion after Reperfusion with Recombinant Tissue-type Plasminogen Activator in Dogs", J. Clin. Invest., 81: 1284-1291 (1988).
Coller, B.S. et al., "Inhibition of Human Platelet Function in Vivo with a Monoclonal Antibody", Ann. Intern. Med., 109: 635-638 (Oct., 1988).
Mickelson, J.K. et al., "Antiplatelet Monoclonal F(ab').sub.2 Antibody Directed Against the Platelet GPIIb/IIIa Receptor Complex Prevents Coronary Artery Thrombosis in the Canine Heart", J. Mol. Cell. Cardiol., 21: 393-405 (1989).
Coller, B.S. et al., "Abolition of In Vivo Platelet Thrombus Formation in Primates With Monoclonal Antibodies to the Platelet GPIIb/IIIa Receptor", Circulation, 80(6): 1766-1774 (1989).
Gold et al., "Pharmacodynamic Study of F(ab').sub.2 Fragments of Murine Monoclonal Antibody 7E3 Directed against Human Platelet Glycoprotein IIb/IIIa in Patients with Unstable Angina Pectoris", J. Clin. Invest., 86: 651-659 (Aug. 1990).
Jordan, R.E. et al., "Evaluation of the Potency and Immunogenicity of 7E3 F(ab').sub.2 and Fab Fragments in Monkeys", Circulation, 82 (Suppl. III): III-661, Abstract No. 2627 (1990).
Yasuda, T. et al., "Lysis of Plasminogen Activator-Resistant Platelet-Rich Coronary Artery Thrombus With Combined Bolus Injection of Recombinant Tissue-Type Plasminogen Activator and Antiplatelet GPIIb/IIIa Antibody", J. Am. Coll. Cardio.l, 16: 1728-1735 (1990).
Bhattacharya, S., et al., "Chimerization of Monoclonal Antibody 7E3 Preserves the GPIIB/IIIA Receptor Blockade and Platelet Functional Inhibition of Murine 7E3", Clin. Res., 39(2):196A (1991).
Ellis et al., "Prospects for the Use of Antagonists to the Platelet Glycoprotein IIb/IIIa Receptor to Prevent Postangioplasty Restenosis and Thrombosis", J. Am. Coll. Cardiol., 17(6): 89B-95B (1991).
Coller et al., "Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents", Ann. N.Y. Acad. Sci., 614: 193-21
Coller Barry S.
Knight David M.
Centocor, Inc.
Chan Christina Y.
Gambel Phillip
LandOfFree
Method of antithrombotic therapy using anti-GPIIb/IIIa antibodie does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of antithrombotic therapy using anti-GPIIb/IIIa antibodie, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of antithrombotic therapy using anti-GPIIb/IIIa antibodie will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2131433